Naurex

Naurex

Developing novel modulators of the NMDA receptor to treat challenging diseases of the brain and central nervous system.

  • Edit
Get premium to view all results
DateInvestorsAmountRound
-investor

€0.0

round
investor

€0.0

round
investor investor investor investor investor investor

€0.0

round
investor investor investor investor investor investor investor

€0.0

round
investor investor investor investor

€0.0

round
investor investor investor investor investor investor investor investor investor investor investor investor investor

€0.0

round

$560m

Valuation: $560m

Acquisition
Total Funding000k
Notes (0)
More about Naurex
Made with AI
Edit

Naurex, a subsidiary of AbbVie, operates in the biopharmaceutical sector, focusing on developing and delivering advanced therapies for complex medical conditions. The company primarily serves healthcare providers and patients, aiming to address unmet medical needs through innovative solutions. Naurex operates in a highly regulated market, adhering to stringent legal and clinical guidelines to ensure the safety and efficacy of its products. The business model revolves around extensive research and development (R&D), clinical trials, and strategic partnerships to bring new treatments to market. Revenue is generated through the sale of approved therapies, licensing agreements, and collaborations with other pharmaceutical entities. Naurex's core competencies include expertise in biologics, small molecules, and novel drug delivery systems, positioning it as a leader in the biopharmaceutical industry.

Keywords: biopharmaceutical, therapies, clinical trials, healthcare, R&D, biologics, small molecules, drug delivery, innovation, partnerships.

Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads